CD40 and neoplasm: A recent preclinical study demonstrated that the combination of an agonist CD40 antibody (αCD40) with RT and dual immune checkpoint inhibitors triggers T cells, achieving the aforementioned transformation of a “cold” tumor into a “hot” tumor and therefore generating long term antitumor immunity [161].